$1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter
Equities analysts expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to report sales of $1.38 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings, with estimates ranging from $1.03 million to $1.72 million. Proteostasis Therapeutics reported sales of $1.72 million in the same quarter last year, which would suggest a negative year over year growth rate of 19.8%. The company is expected to issue its next earnings report on Thursday, November 9th.
On average, analysts expect that Proteostasis Therapeutics will report full-year sales of $1.38 million for the current fiscal year, with estimates ranging from $2.17 million to $5.50 million. For the next financial year, analysts forecast that the firm will report sales of $2.00 million per share. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Proteostasis Therapeutics.
A number of equities analysts have recently commented on PTI shares. Zacks Investment Research lowered Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 30th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a report on Friday, June 30th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $9.00 price target (down from $17.00) on shares of Proteostasis Therapeutics in a report on Wednesday, August 16th.
COPYRIGHT VIOLATION NOTICE: “$1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/09/25/1-38-million-in-sales-expected-for-proteostasis-therapeutics-inc-pti-this-quarter.html.
Shares of Proteostasis Therapeutics (NASDAQ PTI) traded up 4.08% during trading on Friday, reaching $2.04. The company’s stock had a trading volume of 13,825 shares. The stock has a 50-day moving average of $2.08 and a 200-day moving average of $5.13. Proteostasis Therapeutics has a 52-week low of $1.71 and a 52-week high of $16.67. The stock’s market cap is $51.21 million.
Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new stake in Proteostasis Therapeutics during the first quarter valued at $100,000. Dynamic Technology Lab Private Ltd bought a new stake in Proteostasis Therapeutics during the first quarter valued at $112,000. LMR Partners LLP bought a new stake in Proteostasis Therapeutics during the second quarter valued at $127,000. Teachers Advisors LLC boosted its stake in Proteostasis Therapeutics by 21.4% during the fourth quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after buying an additional 2,223 shares during the period. Finally, Trexquant Investment LP boosted its stake in Proteostasis Therapeutics by 1.0% during the first quarter. Trexquant Investment LP now owns 19,790 shares of the company’s stock valued at $155,000 after buying an additional 190 shares during the period. 73.71% of the stock is owned by institutional investors.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.